CRMP2 Antibody [K16M14]

Catalog No.: F5960

    Application: Reactivity:
    • Lane 1: SH-SY5Y, Lane 2: Hela, Lane 3: NIH/3T3, Lane 4: C6
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:30
    1:5000
    1:1000
    1:5000
    Application
    WB, IP, IHC, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    29 kDa 62 kDa,36 kDa, 63 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    CRMP2 Antibody [K16M14] detects endogenous levels of total CRMP2 protein.
    Clone
    K16M14
    Synonym(s)
    CRMP2, ULIP2, DPYSL2, Dihydropyrimidinase-related protein 2, DRP-2, Collapsin response mediator protein 2, N2A3, Unc-33-like phosphoprotein 2, CRMP-2, ULIP-2
    Background
    CRMP2 (collapsin response mediator protein‑2, also known as DPYSL2) is a cytosolic phosphoprotein of the CRMP family that is highly enriched in the developing and adult nervous system and functions as a multifunctional adaptor that links extracellular guidance and neurotrophic cues to intracellular cytoskeletal remodeling, vesicle trafficking, and channel regulation. The protein forms homo‑ and hetero‑tetramers with other CRMPs and contains an N‑terminal globular domain with binding surfaces for tubulin and regulatory enzymes and a C‑terminal flexible tail that carries multiple phosphorylation motifs for kinases such as Cdk5 and GSK3β, oxidation‑sensitive cysteines, and other post‑translational modification sites that tune its activity and subcellular localization. CRMP2 associates with tubulin heterodimers and promotes microtubule polymerization and stabilization, and this activity supports axon specification, elongation, and branching, the multipolar‑to‑bipolar transition of migrating neurons, and the polarized delivery of cargoes along axons, while simultaneous interactions with kinesin‑1, dynein, and endocytic machinery link CRMP2 to axonal transport, protein endocytosis, and recycling of membrane receptors and channels. The protein also participates in presynaptic and postsynaptic organization by regulating vesicle trafficking and synaptic assembly and by controlling the surface density and cycling of voltage‑gated calcium and sodium channels, which positions CRMP2 as a modulator of neuronal excitability and neurotransmitter release in addition to its structural roles in neurite architecture. CRMP2 activity is strongly governed by hierarchical phosphorylation and other modifications: Cdk5‑primed and GSK3β‑mediated phosphorylation at defined C‑terminal residues weakens binding to tubulin and motor proteins and shifts CRMP2 from a growth‑promoting to a growth‑inhibiting state, while dephosphorylation restores interaction with the cytoskeleton and transport complexes, integrating upstream signals from semaphorin–plexin/neuropilin pathways, neurotrophins, and other regulators into precise changes in neurite outgrowth, branching, and guidance. In the mature brain CRMP2 continues to influence synaptic stability and plasticity through effects on microtubule dynamics within dendrites and axon terminals and through regulation of vesicle cycling and receptor trafficking, and mapping of the CRMP2 interactome reveals connections to proteins that orchestrate actin remodeling, endocytosis, and presynaptic release, extending its impact beyond classical axon guidance. Dysregulated CRMP2 expression, phosphorylation, truncation, or mislocalization associates with a wide spectrum of neurological and psychiatric conditions, including Alzheimer’s disease, temporal lobe epilepsy, neuropathic pain, and schizophrenia, where hyperphosphorylated CRMP2 accumulates in neurofibrillary tangles together with tau and SRA1/WAVE1 complexes and correlates with synaptic and structural deficits, and where altered channel trafficking and cytoskeletal control contribute to aberrant excitability and network function.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください